An 8-week exploratory, double-blind, placebo controlled, randomized trial :Evaluation of the efficacy and safety of levetiracetam up to 3000 mg/day (250-500 mg oral tablets in b.i.d. administration) on neuroleptic-induced tardive dyskinesia in subjects with stable axis I psychiatric disorder, aged from at least 18 years to 80 years. - Tardive Dyskinesia-Levetiracetam

CB S.A. Pharma Sector0 个研究点目标入组 70 人开始时间: 2005年3月1日最近更新: 2012年3月19日

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 70

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Written informed consent signed and dated by the subject.
•Male or female, age =18 and = 80 years.
•In- or out patients
•Diagnosis of stable Axis I psychiatric disorder according to the Investigator since at least 6 months prior to the screening visit (V1).
•Stable Neuroleptic-Induced Tardive Dyskinesia (NITD) according to the DSM-IV criteria since at least 1 month prior to the screening visit (V1).
•Tardive Dyskinesia severity defined by a total mean score of hyperkinesia on the SHRS of at least 5 at screening visit (V1) and at baseline visit (V2) before randomization.
•Use of antipsychotics (all types and routes of administration) for at least 6 cumulative months prior to the screening visit (V1) and, if the subject is under treatment, at least one month on a stable dose regimen prior to the screening visit (V1).
•If applicable, stable dose regimen of anticholinergic agents and other drugs used for abnormal movement disorders for the last month prior to the screening visit (V1).
•Able to cooperate and to communicate adequately as judged by the investigator.
•Subjects willing to be videotaped.
•Female subjects without childbearing potential (premenarchal, 2 years post-menopausal, bilateral oophorectomy or bilateral salpingectomy, complete hysterectomy, congenital sterility, bilateral tubal ligation) are eligible. Female subjects with childbearing potential are eligible if they have a negative serum pregnancy test at the screening visit (V1) and if they use a medically accepted contraceptive method for the duration of the trial participation (i.e. oral or non-oral contraceptive method, intra-uterine device, diaphragm with spermicide, male condom with spermicide, female condom, monogamous relationship with vasectomized partner). Abstinence will be considered as an acceptable method of contraception on a case-by-case basis upon discussion with the UCB Clinical Research Physician (CRP) or his/her representative. The subject must understand the consequences and potential risks of inadequately protected sexual activity, be educated about and understand the proper use of contraceptive methods, and undertake to inform the Investigator of any potential change in status.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•Pregnant, lactating or sexually active women with childbearing potential who are not using a medically accepted birth control method.
•The presence of any Axis II condition within 6 months prior to the screening visit (V1).
•History of suicide attempts during the last 10 years prior to the screening visit (V1).
•Huntington’s disease, idiopathic dystonia, Wilson’s disease, Sydenham’s chorea, thyroid dysfunction or spontaneous dyskinesia.
•Dyskinesia due to ill-fitting denture.
•Start of drugs (other than neuroleptics) that can cause dyskinesia (e.g. L-dopa, bromocriptine) within one month prior to the screening visit (V1).
•The presence of alcohol, or other substance abuse disorder as defined by DSM-IV.
•Any medication that may interfere with the absorption, distribution, metabolism, or excretion of the concomitant neuroleptics or levetiracetam during the course of the study.
•Introduction or change in the dose of anticholinergic agents or other drugs intended to control abnormal movements disorders (i.e. branched chain amino acids, vitamin B6 or E, melatonin, neuroleptics,...) within the last month prior to the screening visit (V1).
•Benzodiazepine use not stable i.e. more than 50% change in the daily dose for more than 3 days in subjects with daily benzodiazepine intake, since at least 2 weeks prior to the screening visit (V1).
•Any participation in an investigation of a medication or device within 3 months prior to the screening visit (V1) or during this trial.
•Subject has clinically significant deviations from reference range values for renal function (creatinine clearance – estimated with Cockroft formula - below 50 ml/min) or any of the other laboratory parameters required for this study, as assessed by the Investigator.
•Clinically significant ECG abnormalities;
•Subject has any clinically significant acute or chronic illness (i.e. cardiac, renal or hepatic disease) (as determined during the physical examination or from other information available to the Investigator).
•Known allergic reaction or intolerance to pyrrolidine derivatives and/or excipients (not exclusively but principally to lactose, corn starch, and cellulose) or known history of multiple drug allergies.
•Subject is known to have a terminal illness.
•Subject has any medical condition that might interfere with the subject’s study participation (i.e., serious infection, scheduled elective surgery, etc).
•History of poor compliance with visit schedule or medication intake.
•Investigators, co-investigators, their spouses or children or any trial collaborators may not be included as subject in the trial.
•Subjects having been blood donors during the 3 months before V1 or planning to be blood donator during the trial.
•Subject previously allocated to a trial treatment within this trial.

研究者

发起方

CB S.A. Pharma Sector

相似试验

进行中（未招募）

不适用

An 8-week exploratory, double-blind, placebo controlled, randomized trial :Evaluation of the efficacy and safety of levetiracetam up to 3000 mg/day (250-500 mg oral tablets in b.i.d. administration) on neuroleptic-induced tardive dyskinesia in subjects with stable axis I psychiatric disorder, aged from at least 18 years to 80 years. - Tardive Dyskinesia-LevetiracetamTardive dyskinesia usually occurs after prolonged exposure to antipsychotics and is characterized by abnormal choreiform, athetoic, choreathetoic or rhythmic involuntary movements. The localizations of the neuroleptic-induced TD are mostly the tongue, jaw or extremities.The abnormal movements increase with emotional arousal and decrease with relaxation. The movements are absent during sleep.MedDRA version: 7.1Level: LLTClassification code 10013928

EUCTR2004-001302-27-DECB S.A. Pharma Sector70

进行中（未招募）

1 期

An 8-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patients infected with SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2)COVID-19 development in hospitalized patients infected with SARS-CoV-2MedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862

EUCTR2020-005849-16-BGKinarus AG432

进行中（未招募）

1 期

EUCTR2020-005849-16-DEKinarus AG432

进行中（未招募）

不适用

An 8-week study to evaluate the efficacy (blood pressure lowering effect) and safety of LCZ696 given alone and in combination with amlodipine

EUCTR2013-001643-30-ESovartis Farmacéutica S. A1,386

进行中（未招募）

不适用

An 8-week study to evaluate the efficacy (blood pressure lowering effect) and safety of LCZ696 given alone and in combination with amlodipine

EUCTR2013-001643-30-SKovartis Pharma Services AG1,386